Lantus

Lantus is a long-acting basal insulin analog used in the treatment of diabetes mellitus. It is manufactured by the French pharmaceutical company Sanofi and its primary active ingredient is insulin glargine. The medication is designed to provide a steady, peakless level of insulin over approximately 24 hours, helping to control blood sugar levels between meals and overnight.

Medical uses

Lantus is indicated for once-daily subcutaneous administration to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. It is often used as part of a comprehensive treatment regimen that may include rapid-acting insulin analogs, oral hypoglycemic agents, diet, and exercise. Clinical studies, such as those reviewed by the U.S. Food and Drug Administration, have demonstrated its efficacy in reducing levels of glycated hemoglobin. It is not recommended for the treatment of diabetic ketoacidosis or via intravenous therapy.

Side effects

The most common adverse reaction associated with Lantus is hypoglycemia, which can be severe. Other frequent side effects include injection site reactions, such as pain, redness, or lipodystrophy. Allergic reactions, including pruritus and rash, have been reported. Weight gain and peripheral edema may also occur. As with all insulin therapies, there is a risk of hypokalemia, and patients should be monitored, particularly those using medications like potassium-lowering diuretics or angiotensin-converting enzyme inhibitors.

Pharmacology

Insulin glargine is a recombinant DNA human insulin analog that differs from human insulin by the replacement of an asparagine residue at position A21 with glycine and the addition of two arginine residues to the C-terminus of the B-chain. These modifications shift the isoelectric point, making the molecule less soluble at physiological pH. After injection into the subcutaneous tissue, it forms microprecipitates that slowly release the insulin, resulting in a prolonged duration of action with no pronounced peak. It acts by binding to the insulin receptor on cells, facilitating the uptake of glucose and regulating metabolism.

History

Insulin glargine was developed by researchers at Hoechst AG, which later became part of Aventis and ultimately Sanofi. It received its first marketing approval from the European Medicines Agency in 2000, followed by approval from the U.S. Food and Drug Administration later that same year. Its development represented a significant advancement in diabetes care by providing a more predictable and stable basal insulin compared to earlier formulations like NPH insulin. Subsequent formulations, such as Lantus SoloStar, a prefilled pen device, were later introduced to improve ease of use.

Society and culture

Lantus has been a major product for Sanofi, generating significant global revenue and becoming one of the world's best-selling insulin brands. Its patent expiration in the United States and European Union led to the development and approval of follow-on products, often referred to as biologics, such as Basaglar from Eli Lilly and Company. The cost of insulin, including Lantus, has been a subject of intense debate and scrutiny by organizations like the American Diabetes Association and government bodies, influencing healthcare policy discussions around drug pricing and access. Category:Antidiabetic drugs Category:Insulins Category:Sanofi